DPYD genotype-guided dose individualisation of fluoropyrimidine therapy: who and how? - Authors' reply

Lancet Oncol. 2019 Feb;20(2):e67. doi: 10.1016/S1470-2045(19)30010-5.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Capecitabine
  • Dihydrouracil Dehydrogenase (NADP) / genetics*
  • Genotype
  • Humans
  • Neoplasms*
  • Prospective Studies

Substances

  • Capecitabine
  • Dihydrouracil Dehydrogenase (NADP)